Clinical Trial Update: VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

View source ↗

Summary

A clinical trial evaluating VEGF as a prognostic factor for white matter damage in preterm infants has been withdrawn from ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• White Matter Damage in Preterm Infants

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Preterm Infants With White Matter Damage, Preterm Infants Developing Normally | Status: WITHDRAWN